Caphosol
Natural health product licensed in Canada
- Licence holder
- Superna Life Sciences Inc.
- NPN or DIN-HM
- 80026902
- Status
- Active licence
- Licence date
- 16 August 2011
- Revision date
- Not provided
- Form
- Liquide oral
- Route of administration
- Buccale
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| Phosphate disodique Source : Phosphate disodique | 9.5 mg |
| Chlorure de sodium Source : Chlorure de sodium | 170.8 mg |
Non-medicinal ingredients
Eau purifiée
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 15 ampoule | minimum: 4 Tous les jours ; maximum: 10 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Caphosol reduces the severity, duration and pain associated with oral mucositis caused by chemotherapy and/or radiation therapy.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80026902
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.